Bachem signs 7-year agreement with Eli Lilly to accelerate oligonucleotide production
Bachem, the Swiss pharmaceutical company, has partnered with Eli Lilly, an American pharmaceutical firm, to further advance the development of oligonucleotide-based drug substances